Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
31 studies found for:    Northwestern AND Headache
Show Display Options
Rank Status Study
1 Recruiting Incidence of Headache Following an Unintentional Dural Puncture
Conditions: Postdural Puncture Headache;   Post-Lumbar Puncture Headache;   Cerebrospinal Fluid Leaks
Interventions: Drug: Morphine;   Drug: Saline
2 Recruiting A Comparison of Dexamethasone and Triamcinolone for Ultrasound-guided Occipital C2 Nerve Blocks
Condition: Headache
Interventions: Drug: Triamcinolone;   Drug: Dexamethasone;   Drug: Normal Saline;   Drug: Bupivacaine
3 Unknown  Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury
Condition: Brain Concussion
Interventions: Drug: Ibuprofen;   Drug: Acetaminophen
4 Completed Cervicogenic Headache Dose-Response
Condition: Cervicogenic Headache
Interventions: Other: Spinal Manipulation;   Other: Light Massage
5 Completed
Has Results
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Condition: Parkinson Disease
Interventions: Drug: Isradipine CR 5mg;   Drug: Isradipine CR 10mg;   Drug: Isradipine CR 20mg;   Drug: Placebo
6 Completed Premium Migraine Trial
Conditions: Migraine Headaches;   Patent Foramen Ovale
Interventions: Other: Sham Procedure;   Device: AMPLATZER PFO Occluder
7 Recruiting A Study of LY2951742 in Participants With Episodic Cluster Headache
Condition: Episodic Cluster Headache
Interventions: Drug: LY2951742;   Drug: Placebo
8 Recruiting A Study of LY2951742 in Participants With Chronic Cluster Headache
Condition: Chronic Cluster Headache
Interventions: Drug: LY2951742;   Drug: Placebo
9 Enrolling by invitation A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
Conditions: Episodic Cluster Headache;   Chronic Cluster Headache
Intervention: Drug: Galcanezumab
10 Unknown  Clinical Evaluation of QFlu Combo Test
Conditions: Cough;   Myalgia;   Nasal Obstruction;   Sore Throat;   Headache;   Fatigue;   Fever
Intervention:
11 Active, not recruiting A Study of LY2951742 in Participants With Migraine Headache
Condition: Migraine Headache
Interventions: Drug: LY2951742;   Drug: Placebo
12 Active, not recruiting Evaluation of LY2951742 in the Prevention of Chronic Migraine
Condition: Chronic Migraine
Interventions: Drug: LY2951742;   Drug: Placebo
13 Terminated ESCAPE Migraine Trial
Conditions: Migraine Disorders;   Heart Septal Defects, Atrial
Interventions: Device: PFO Closure with Premere investigational device.;   Drug: Medical management/current medications per standard of care by personal physician.
14 Recruiting Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention
Condition: Migraine, With or Without Aura
Interventions: Drug: AGN-241689;   Drug: Placebo-matching AGN-241689
15 Active, not recruiting Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-2 Study
Condition: Migraine
Interventions: Drug: LY2951742;   Drug: Placebo
16 Completed Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
Condition: Acute Migraine
Interventions: Drug: Lasmiditan 100 mg;   Drug: Lasmiditan 200 mg;   Drug: Placebo (matches lasmiditan doses)
17 Completed Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1
Conditions: AIDS Dementia Complex;   HIV Infections
Interventions: Drug: Nimodipine;   Drug: Zidovudine
18 Recruiting Safety and Immune Response to a Clade C DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Protein/MF59 vaccine;   Biological: Placebo
19 Enrolling by invitation An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
Condition: Migraine, With or Without Aura
Interventions: Drug: Ubrogepant;   Drug: Placebo-matching Ubrogepant;   Drug: Usual Care
20 Recruiting Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
Condition: Migraine, With or Without Aura
Interventions: Drug: Ubrogepant;   Drug: Placebo-matching Ubrogepant

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.